Schizophrenia trials recruiting in Ohio

All Schizophrenia trials nationally

Cities in Ohio

Recruiting trials in Ohio

• 52-week Open Label Safety-Tolerability Study
  NCT07369154 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Canton
• A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
  NCT07459647 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: North Canton, West Chester
• A Study of Brenipatide in Adult Participants With Schizophrenia
  NCT07410507 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Ohio: Independence
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Ohio: Dayton, Independence
• A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
  NCT07191483 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Ohio: North Canton
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Ohio: Columbus, Dayton, Independence
• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
  NCT06947941 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · Ohio: Cleveland, Independence
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  NCT07105111 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Independence
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
  NCT07288567 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati
• A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
  NCT07424404 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, West Chester
• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
  NCT06894212 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: North Canton
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
  NCT07379827 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Mason
• Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
  NCT03817502 · Phase: Phase 3 · Ages: 13 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati
• Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
  NCT07101094 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Westlake
• NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
  NCT07105098 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: North Canton
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
  NCT07114874 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: North Canton
• Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
  NCT04368039 · Phase: Not applicable (e.g. observational or device study) · Ages: 15 Years to 35 Years · Sex: All (male and female) · Ohio: Columbus
• REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
  NCT07006935 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: All (male and female) · Ohio: Cleveland
• Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
  NCT07686263 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: Cincinnati
• Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
  NCT06229210 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Ohio: Avon Lake, Cincinnati, Garfield Heights
• Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
  NCT05648591 · Phase: Phase 4 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, Garfield Heights, Westlake
• Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
  NCT07363577 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Ohio: North Canton
• Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
  NCT05303064 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Ohio: Cincinnati, West Chester